3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Myelodysplastic Syndromes
2
Thrombocythemia, Essential
1
Rhabdomyosarcoma
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Hepatoblastoma
1
Gliosarcoma
1
Glioblastoma
1
Ependymoma
1
Disease
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Stem Neoplasms
1
Astrocytoma
1
Interventions
fludarabine phosphate
16
Cyclophosphamide
15
Peripheral Blood Stem Cell Transplantation
10
Tacrolimus
9
Busulfan
9
Whole-Body Irradiation
8
Mycophenolic Acid
8
fludarabine
6
Methotrexate
6
Cyclosporine
6
Radiotherapy
5
ruxolitinib
4
Biopsy
4
Antilymphocyte Serum
4
Specimen Handling
3
Decitabine
3
peginterferon alfa-2a
2
givinostat hydrochloride
2
givinostat
2
bomedemstat
2
Stem Cell Transplantation
2
Prednisone
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
Methylprednisolone
2
Melphalan
2
Imatinib Mesylate
2
Filgrastim
2
Etoposide
2
Cytarabine
2
Aspirin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Thrombocythemia, Essential
×
imetelstat
×
Clear all
NCT01243073
2016-01-26
ET/PV
Geron Corporation
Phase 2
Completed
20 enrolled